Lidia Karabon

Summary

Country: Poland

Publications

  1. Karabon L, Markiewicz M, Kosmaczewska A, Partyka A, Pawlak Adamska E, Tomkiewicz A, et al. Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation. Immunol Lett. 2015;165:52-9 pubmed publisher
    ..024-1.311, p=0.018). Our results indicate that both donor and recipient CTLA-4 mRNA as well as recipient membrane protein expression levels measured before transplantation may be considered as prognostic factors for aGvHD development. ..
  2. Karabon L, Markiewicz M, Partyka A, Pawlak Adamska E, Tomkiewicz A, Dzierzak Mietla M, et al. A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Immunogenetics. 2015;67:295-304 pubmed publisher
    ..008). Our data suggest that the CT60G>A[GG] genotype in the recipient has an impact on aGvHD development, especially in patients receiving transplants from unrelated donors together with the myeloablative conditioning regimen. ..
  3. Karabon L, Pawlak E, Tomkiewicz A, Jedynak A, Passowicz Muszyńska E, Zajda K, et al. CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol. 2011;72:947-54 pubmed publisher
    ..1554+4GT(8_15)[>10] was associated with a decreased overall survival rate. In conclusion, the constellation of specific alleles in CTLA-4, CD28, and ICOS genes contributes to the susceptibility and clinical course of NSCLC. ..
  4. Karabon L, Pawlak Adamska E, Tomkiewicz A, Jedynak A, Kielbinski M, Woszczyk D, et al. Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res. 2012;18:219-26 pubmed publisher
    ..79, 95%CI: 2.08-6.89, p?=?0.00001). These findings indicate that genetic variations in the CTLA-4 gene play role in susceptibility to multiple myeloma and warrant further investigation through replication studies. ..
  5. Karabon L, Kosmaczewska A, Bilinska M, Pawlak E, Ciszak L, Jedynak A, et al. The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology. 2009;128:e787-96 pubmed publisher
    ..e. CT60A and Jo31T) may lead to inadequate down-regulation of ongoing T-cell responses in these patients and, as a consequence, earlier progression of disease from the RR form to the SP form. ..
  6. Karabon L, Jedynak A, Giebel S, Wołowiec D, Kielbinski M, Woszczyk D, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens. 2011;78:129-38 pubmed publisher
    ..007). Our results indicate that the pattern of inhibitory/activating KIR genes, together with their HLA ligands, is associated with susceptibility to B-CLL and affects the clinical course of this disease. ..
  7. Partyka A, Tupikowski K, Kolodziej A, Zdrojowy R, Halon A, Malkiewicz B, et al. Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population. Urol Oncol. 2016;34:419.e13-9 pubmed publisher
    ..08-1.96; Pcorrected = 0.05). Our results indicate that polymorphisms rs1982809 situated in 3' UTR nearby region of BTLA gene might be considered as low-penetrating risk factor for RCC, but results have to be confirmed in further studies. ..
  8. Karabon L, Tupikowski K, Tomkiewicz A, Partyka A, Pawlak Adamska E, Wojciechowski A, et al. Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?. Pathol Oncol Res. 2017;23:837-843 pubmed publisher
    ..78) for carriers of both susceptibility alleles as compared to carriers of protective genotypes (p = 0.03). The CTLA-4c.49A>G and CTLA-4g.319C>T SNPs might be considered as low risk susceptibility locus for PCa. ..
  9. Karabon L, Partyka A, Jasek M, Lech Maranda E, Grzybowska Izydorczyk O, Bojarska Junak A, et al. Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. Arch Immunol Ther Exp (Warsz). 2016;64:137-145 pubmed publisher
    ..0.026 ± 0.012, p = 0.03). Our results indicate that rs1982809 BTLA gene polymorphism is associated with mRNA expression level and that variations in the BTLA gene might be considered as potentially low-penetrating CLL risk factor. ..